SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors
December 04 2019 - 4:05PM
SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical
device company dedicated to solving musculoskeletal disorders of
the sacropelvic anatomy, today announced that Jeri Hilleman has
joined its Board of Directors, effective immediately. Hilleman will
also serve as chair of the audit committee.
“I am excited to welcome Jeri to our Board of
Directors,” said Jeff Dunn, President, Chief Executive Officer, and
Chairman of SI-BONE. “Her extensive experience as a public company
CFO provides deep expertise across public company leadership,
capital raises and business development. I look forward to her
insight and guidance as we continue to advance our role in
transforming the treatment of sacropelvic disorders.”
Hilleman brings over 20 years of executive leadership and
financial experience, primarily from the healthcare sector. She
currently serves as a member of the Board of Directors and Audit
Committee Chair of Novocure (Nasdaq: NVCR), a commercial
international oncology company delivering a novel device therapy
for solid tumors called Tumor Treating Fields; and Minerva
Neurosciences (Nasdaq: NERV), a clinical stage company focused on
innovative solutions for patients with central nervous system
diseases.
Hilleman has previously served as chief financial officer of
several public companies including Intersect ENT (NASDAQ: XENT),
Amyris (NASDAQ: AMRS), Symyx Technologies (acquired), Ocera
(acquired) and Cytel (acquired). Hilleman holds an A.B. from Brown
University and an M.B.A. from the Wharton Graduate School of
Business. She is also a member of the 1999 class of Henry Crown
Fellows and the Aspen Global Leadership Network at the Aspen
Institute.
“I am honored to join the SI-BONE Board of Directors,” said
Hilleman. “SI-BONE has already made tremendous progress
transforming sacropelvic treatment and I am excited to help them as
they continue to expand their commercial footprint.”
About SI-BONE, Inc.
SI-BONE is a medical device company that
pioneered minimally invasive surgery of the SI joint with the iFuse
Implant System. Studies have shown that the SI joint can be a
source of pain in 15% to 30% of chronic low back pain. The
iFuse Implant™, commercially available since 2009, is the only SI
joint fusion device supported by multiple prospective clinical
studies, including two RCTs, showing improved pain, patient
function and quality of life resulting from treatment. There are
over 75 peer-reviewed publications demonstrating the safety,
durable effectiveness, and biomechanical and economic benefits
unique to the iFuse Implant (www.si-bone.com/results). This
body of evidence has enabled multiple government and private
insurance payors to establish coverage of the SI joint fusion
procedure exclusively when performed with the iFuse Implant
System.
The iFuse Implant System is intended for
sacroiliac fusion for conditions including sacroiliac joint
dysfunction that is a direct result of sacroiliac joint disruption
and degenerative sacroiliitis. This includes conditions whose
symptoms began during pregnancy or in the peripartum period and
have persisted postpartum for more than 6 months. The iFuse
Implant System is also intended for sacroiliac fusion to augment
immobilization and stabilization of the sacroiliac joint in
skeletally mature patients undergoing sacropelvic fixation as part
of a lumbar or thoracolumbar fusion.
There are potential risks associated with the
iFuse Implant System. It may not be appropriate for all
patients and all patients may not benefit. Rx Only. For
indications, risks, and safety information visit:
www.si-bone.com/risks.
For more information, visit www.si-bone.com and follow us on
Twitter at @siboneinc.
SI-BONE and iFuse Implant System are registered
trademarks of SI-BONE, Inc. iFuse Implant is a trademark of
SI-BONE, Inc. ©2019 SI-BONE, Inc. All Rights
Reserved. 10587.120419
Investor Contacts:
Lynn Lewis or Carrie Mendivil
investors@SI-BONE.com
415-937-5405
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024